BIRC6 AS A NOVEL THERAPEUTIC TARGET IN TRIPLE NEGATIVE BREAST CANCER

GÓMEZ BERGNA SANTIAGO MANUEL; MARCHESINI ABRIL; GOTTARDO MARÍA FLORENCIA; FARINA HERNÁN G.; ROMANOWSKI VÍCTOR; PIDRE MATIAS LUIS

Buenos Aires

Congreso; LXV REUNIÓN ANUAL DE LA SOCIEDAD ARGENTINA DE INVESTIGACIÓN CLÍNICA (SAIC); 2020

SAIC

BIRC6 (baculoviral IAP repeat-containing protein 6) is a member of the inhibitorsof apoptosis protein family thought to play an important role in the progression orchemoresistance of many cancers. The aim of this study was to investigate therole of BIRC6 in triple negative breast cancer (TNBC).Firstly, we analyzed BIRC6 mRNA expression levels and Copy NumberVariations (CNV) in three Breast Cancer databases (TCGA) using cBioPortal andUSCSXena platforms comparing clinical and molecular attributes. In addition, weanalyzed the BIRC6 expression in murine (F3II) and human (MDA-MB-231)TNBC cell lines by immunofluorescence. Moreover, we used a recombinantbaculovirus able to silence BIRC6 previously constructed in our lab. Then, wedetermined apoptosis levels in F3II cells by TUNEL.Our bioinformatics results showed that there was a differential expression ofBIRC6 in cancer samples compared to normal samples (normal= -0,372±0,395,cancer= 0,113±1,055; t-test, p